MCED Legislative Comparison
The following chart is a section-by-section summary of the MCED legislation, comparing the legislation introduced in the 118th Congress with the version introduced in the 119th Congress.
Group Letter Supporting MCED Legislation
September 24, 2025
ACS CAN joined with 50 other organizations to applaud Representatives Jodey Arrington (R-TX) and Terri Sewell (D-AL) for sponsoring and prioritizing the passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 842). This breakthrough legislation will provide the Medicare program with the authority to cover multi-cancer early detection (MCED) tests once the tests have been approved by the FDA and clinical benefit has been shown. Understanding the crucial role of early detection, H.R. 842 provides the Medicare program with the authority to cover MCED tests, innovative tests that have the potential to detect many types of cancers at earlier stages. Coverage of MCED tests will add another option for early detection of cancer. Moreover, the legislation maintains Medicare’s existing coverage of breast, cervical, prostate, colorectal, and lung cancer screening tests. It further facilitates gradual coverage implementation including updates to the effective date, a phase-in of coverage by age, and alignment in the payment rate with analogous tests established in existing law.